Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes

Clinical and Experimental Immunology

Volumn 172, Issue 3, 2013, Pages 375-382

  Cabrera, S M ^a   Colvin, S C ^a   Tersey, S A ^a   Maier, B ^a   Nadler, J L ^b   Mirmira, R G ^a  

^a INDIANA UNIVERSITY   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Animal models (mice rats); Autoimmunity; Insulitis; Lymph nodes; Non obese diabetic (NOD) mouse; Regulatory T cells; Type 1 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; MK 626; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DESTRUCTION; CELL PROTECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE TOLERANCE; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MONOTHERAPY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1; TRIAZOLES;

EID: 84876719833     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12068     Document Type: Article

References (42)

1. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23:447-485.
2. Tian L, Gao J, Hao J etal. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 2010; 151:3049-3060.
3. Menard V, Jacobs H, Jun HS, Yoon JW, Kim SW. Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice. Pharm Res 1999; 16:1059-1066.
4. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158:2947-2954.
5. Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui S. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. An observation in nonobese diabetic (NOD) mice. Diabetes 1982; 31:749-753.
6. Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992; 89:174-178.
7. Atkinson MA, Maclaren NK, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990; 39:933-937.
8. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991; 88:10252-10256.
9. Gale EAM, Bingley PJ, Emmett CL, Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363:925-931.
10. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346:1685-1691.
11. Sherry N, Hagopian W, Ludvigsson J etal. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487-497.
12. Wherrett DK, Bundy B, Becker DJ etal. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378:319-327.
13. Skyler JS, Krischer JP, Wolfsdorf J etal. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care 2005; 28:1068-1076.
14. Edmondson SD, Mastracchio A, Mathvink RJ etal. (2 S, 3 S)-3-Amino-4-(3, 3-difluoropyrrolidin-1-yl)- N, N-dimethyl-4-oxo-2-(4-[1, 2, 4]triazolo[1, 5- a]- pyridin-6-ylphenyl)butanamide: a aelective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2006; 49:3614-3627.
15. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696-1705.
16. Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. J Endocrinol 2012; 214:381-387.
17. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998; 161:55-70.
18. Reinhold D, Bank U, Bühling F etal. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol Lett 1997; 58:29-35.
19. Reinhold D, Bank U, Bühling F etal. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology 1997; 91:354-360.
20. Preller V, Gerber A, Wrenger S etal. TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol 2007; 178:4632-4640.
21. Leoni F, Fossati G, Lewis EC etal. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005; 11:1-15.
22. Lewis EC, Blaabjerg L, Storling J etal. The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro. Mol Med 2011; 17:369-377.
23. Larsen L, Tonnesen M, Ronn SG etal. Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia 2007; 50:779-789.
24. Lundh M, Christensen DP, Damgaard Nielsen M etal. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. Diabetologia 2012; 55:2421-2431.
25. Chou DH-C, Holson EB, Wagner FF etal. Inhibition of histone deacetylase 3 protects Beta cells from cytokine-induced apoptosis. Chem Biol 2012; 19:669-673.
26. Tao R, de Zoeten EF, Ozkaynak E etal. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13:1299-1307.
27. Reilly CM, Thomas M, Gogal R etal. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J Autoimmun 2008; 31:123-130.
28. Leoni F, Zaliani A, Bertolini G etal. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99:2995-3000.
29. Tersey SA, Nishiki Y, Templin AT etal. Islet β-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. Diabetes 2012; 61:818-827.
30. Evans-Molina C, Robbins RD, Kono T etal. PPAR-{gamma} activation restores islet function in diabetic mice through reduction of ER stress and maintenance of euchromatin structure. Mol Cell Biol 2009; 29:2053-2067.
31. Cabrera SM, Rigby MR, Mirmira RG. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med 2012; 12:1261-1272.
32. Chen W, Jin W, Hardegen N etal. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-1886.
33. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes A-MB, Herold KC. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 2006; 55:3238-3245.
34. Robbins RD, Tersey SA, Ogihara T etal. Inhibition of deoxyhypusine synthase enhances islet {beta} cell function and survival in the setting of endoplasmic reticulum stress and type 2 diabetes. J Biol Chem 2010; 285:39943-39952.
35. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H etal. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-2152.
36. Atkinson MA, Bluestone JA, Eisenbarth GS etal. How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes 2011; 60:1370-1379.
37. Richon VM, Emiliani S, Verdin E etal. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95:3003-3007.
38. Patel T, Patel V, Singh R, Jayaraman S. Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice. Immunol Cell Biol 2011; 89:640-649.
39. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005; 48:616-620.
40. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011; 28:1176-1181.
41. Ryan EA, Paty BW, Senior PA etal. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060-2069.
42. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26:832-836.